EstesC, RazaviH, LoombaR, YounossiZ, SanyalAJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology, 2018; 67:123–133.
2.
YounossiZ, AnsteeQM, MariettiM, et al.Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol, 2018; 15:11–20.
3.
ChalasaniN, YounossiZ, LavineJE, et al.The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology, 2018; 67:328–357.
4.
JaruvongvanichV, SanguankeoA, RiangwiwatT, UpalaS. Testosterone, sex hormone-binding globulin and nonalcoholic fatty liver disease: A systematic review and meta-analysis. Ann Hepatol, 2017; 16:382–394.
5.
WuJ, YaoXY, ShiRX, LiuSF, WangXY. A potential link between polycystic ovary syndrome and non-alcoholic fatty liver disease: An update meta-analysis. Reprod Health, 2018; 15:77.
6.
ParkJP, LeeHS, OhJ, LeeY. Serum testosterone level within normal range is positively associated with nonalcoholic fatty liver disease in premenopausal but not postmenopausal women. J Womens Health (Larchmt), 2019; 28:1077–1082.
7.
SarkarM, WellonsM, CedarsMI, et al.Testosterone levels in pre-menopausal women are associated with nonalcoholic fatty liver disease in midlife. Am J Gastroenterol, 2017; 112:755–762.
8.
DingEL, SongY, MalikVS, LiuS. Sex differences of endogenous sex hormones and risk of type 2 diabetes: A systematic review and meta-analysis. JAMA, 2006; 295:1288–1299.
9.
LovejoyJC, BrayGA, BourgeoisMO, et al.Exogenous androgens influence body composition and regional body fat distribution in obese postmenopausal women—A clinical research center study. J Clin Endocrinol Metab, 1996; 81:2198–2203.
10.
LazoM, ZebI, NasirK, et al.Association between endogenous sex hormones and liver fat in a multiethnic study of atherosclerosis. Clin Gastroenterol Hepatol, 2015; 13:1686–1693.e2.
11.
CorbouldA.Effects of androgens on insulin action in women: Is androgen excess a component of female metabolic syndrome?. Diabetes Metab Res Rev, 2008; 24:520–532.
12.
MoghettiP, TosiF, CastelloR, et al.The insulin resistance in women with hyperandrogenism is partially reversed by antiandrogen treatment: Evidence that androgens impair insulin action in women. J Clin Endocrinol Metab, 1996; 81:952–960.
13.
CorbouldA.Effects of spironolactone on glucose transport and interleukin-6 secretion in adipose cells of women. Horm Metab Res, 2007; 39:915–918.
14.
KarashimaS, YonedaT, KometaniM, et al.Comparison of eplerenone and spironolactone for the treatment of primary aldosteronism. Hypertens Res, 2016; 39:133–137.
15.
Muneyyirci-DelaleO, KaplanJ, JoulakI, YangL, Von GizyckiH, NacharajuVL. Serum free fatty acid levels in PCOS patients treated with glucophage, magnesium oxide and spironolactone. Gynecol Endocrinol, 2013; 29:474–477.
16.
PolyzosSA, KountourasJ, MantzorosCS, PolymerouV, KatsinelosP. Effects of combined low-dose spironolactone plus vitamin E vs vitamin E monotherapy on insulin resistance, non-invasive indices of steatosis and fibrosis, and adipokine levels in non-alcoholic fatty liver disease: A randomized controlled trial. Diabetes Obes Metab, 2017; 19:1805–1809.
